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Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract have undergone a remarkable evolution
in how they are perceived, classified, approached, diagnosed and managed over the last 30 years. Gastrointestinal
stromal tumors (GIST) account for approximately 1% to 3% of all malignant GI tumors. The clinical features can vary
depending on the anatomic location, size and aggressiveness of the tumor. Metastatic GIST represents a successful
example of molecular targeted therapy. In this comprehensive review, we discuss the epidemiology, clinical features
and diagnostic modalities for GIST. We also describe treatment options for early stage, locally advanced and
metastatic GIST. Indications for neoadjuvant and adjuvant therapy along with duration of therapy are also
explained. A brief discussion of latest biomarkers and updates from recent meetings is also provided.Introduction
Stromal or mesenchymal neoplasms affecting the GI
tract have undergone a remarkable evolution in how
they are perceived, classified, approached, diagnosed and
managed over the last 30 years. A major breakthrough
occurred with the discovery of expression of the CD117
antigen by almost all gastrointestinal stromal tumors
(GIST)[1]. The other group of spindle cell neoplasms
arising in the GI tract includes lipomas, schwannomas,
hemangiomas, usual leiomyomas and leiomyosarcomas
are typically CD117-negative [2]. The CD117 molecule is
part of the KIT (c-kit) receptor tyrosine kinase that is a
product of the KIT proto-oncogene (Figure 1). GIST re-
search and clinical care sets another great example of
translational research that turns laboratory discovery to
successful clinical application. From this fundamental
mechanistic understanding of GIST, a series of world-
wide investigations and trials have developed novel and
effective ways to approach patients with this disease. In
this review, we discuss the basics of GIST and highlight
recent advances and their relevance to current clinical
practice as well as future directions.* Correspondence: delong_liu@nymc.edu
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GISTs account for approximately 1% to 3% of all malig-
nant GI tumors [3]. Epidemiologic data such as that from
Surveillance, Epidemiology and End Results (SEER) pro-
gram are difficult to interpret since the earlier definition
of "malignant GIST" was derived from criteria published
in 1990, before GIST was molecularly characterized [4].
The estimated incidence of GIST has been revised up-
ward to approximately 5,000 new cases per year in the
United States (US) [5,6]. The most dependable inter-
national epidemiologic data are from population-based
studies that reexamined all cases of potential GIST [7-
10]. These studies reported annual incidence of GIST
ranging from 11 to 14.5 per million population. More re-
cent studies suggest that the incidentally detected sub-
centimeter gastric GIST lesions may be more frequent
than expected [11,12].
Clinical presentation
The clinical features can vary depending on the anatomic
location, size and aggressiveness of the tumor. Most symp-
tomatic patients have tumors larger than 5 cm in maximal
dimension. In a series of cases with leiomyomas and leio-
myosarcoma (without separation of the GISTs), there were
three major presentations [13], GI bleeding (40%), abdom-
inal mass (40%) and abdominal pain (20%). Two-thirds of
patients had GI bleeding while 25 to 40% presented with
an intestinal obstruction. Intestinal perforation can also
occur uncommonly. Rare patients have been describedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The structure of KIT/CD117 and the signal
transduction. KIT is a transmembrane receptor type tyrosine knase.
The stem cell factor/KIT ligand binds to KIT and activates the KIT
tyrosine kinase. The phosphorylated (activated) KIT then activates its
substrates which lead to cell proliferation.
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neoplastic production of insulin like growth factor II [14].
Other symptoms at presentation may include nausea,
vomiting, anorexia, and weight loss. The vast majority of
GIST metastases at presentation are intra-abdominal, ei-
ther to the liver, omentum or peritoneal cavity [15]. Me-
tastases to lymph nodes or to extra-abdominal sites via
lymphatics are rare.
Diagnostic imaging
GIST should always be among the differential diagnosis
of an intra-abdominal non-epithelial malignancy. CT is
essential for evaluating the primary tumor and for accur-
ate staging. Magnetic resonance imaging (MRI) has a
comparable diagnostic yield [16] and lacks radiation ex-
posure. However, CT is preferred initially for screening
and staging. CT is better at global evaluation of the ab-
domen, especially the hollow viscera, than MRI. MRI
may be preferred for GISTs at specific sites, such as rec-
tum or liver. Tumors that are greater than 5 cm, lobu-
lated, enhance heterogeneously, and have mesenteric fat
infiltration, ulceration, regional lymphadenopathy, or an
exophytic growth pattern on CT are more likely to
metastasize [17-21]. In contrast, GISTs with less meta-
static potential tend to enhance in a homogeneous pat-
tern, and often show an endoluminal growth pattern.
CT or MRI scanning can assess the decrease in lesion
density which can be an early marker of beneficial re-
sponse in GIST patients treated with TKI drugs [22].
Routine clinical practice rarely requires Positron Emis-
sion Tomography (PET) imaging of GIST for clinical
care [23]. PET imaging may have the advantage of
detecting small lesions at least 1 cm in size because nei-
ther the normal bowel nor omentum takes up thefluorodeoxyglucose (FDG) tracer with excess avidity.
The reported sensitivity of PET for GIST is 86 to 100%
[24,25]. PET can be useful for detecting an unknown pri-
mary site or resolving ambiguities from CT [26]. On
upper GI endoscopy, a smooth, mucosa-lined protrusion
of the bowel wall, with or without signs of bleeding and
ulceration may be seen [27]. However, endoscopic biop-
sies using standard techniques usually do not obtain suf-
ficient tissue for a definite diagnosis [28]. Endoscopic
ultrasound (EUS) -guided fine-needle biopsy forceps also
may not yield enough tissue, but might exclude other
lesions that arise sub-mucosally. Snare biopsies can re-
sult in perforation and generally should be avoided ex-
cept in carefully selected cases [28]. A preoperative
biopsy is not generally recommended for a resectable le-
sion in which there is a high suspicion for GIST, and the
patient is otherwise operable. However, a biopsy should
be done to confirm the diagnosis particularly when
metastatic disease is present or suspected. If preopera-
tive imatinib is considered in a patient who has a large
locally advanced lesion thought to represent GIST, a bi-
opsy should be done. An EUS-guided biopsy (in carefully
selected patients and preferably of the primary lesions)
is more desirable than a percutaneous biopsy [29].
Histopathology and cytology
Differentiation between GISTs and other tumors is typ-
ically based upon immunohistochemistry (IHC) and mo-
lecular analysis. Histologic findings seen on hematoxylin
and eosin-stained sections do not reliably or specifically
relate to the immunophenotype nor the molecular gen-
etics of the lesions [30]. GISTs characteristically stain
positive for CD117 antigen (KIT) on IHC assays. The
level of expression can vary from generally diffuse and
strong (most common in the spindle cell subtype) to
focal and weakly positive in a dot-like pattern (the
epithelioid subtype) [5]. CD34 expression is not specific
for GIST and it can also be seen in desmoid tumors
[5,31,32]. About 95% of GISTs are KIT-positive, while 60
to 70% are positive for CD34, 30 to 40% are positive for
smooth muscle actin, 5% for S-100 protein, and 1 to 2%
are positive for desmin or keratin [2,5,32]. Identification
of CD117-negative GIST remains a diagnostic challenge,
and these are most likely to be driven by alternative
kinases like PDGFRA [33]. The antigen known as DOG-
1 (“discovered on GIST-1”) can also help to identify cer-
tain KIT-negative GIST lesions as DOG-1 expression is
quite specific for GIST [34,35].
Prognostic features of GIST
The current consensus is to treat all GISTs, including
those with a benign appearance by conventional histo-
pathologic criteria, as having the potential to behave in a
malignant fashion [5,23]. This is due to the biologic
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long follow-up, virtually all GISTs have the potential for
malignant behavior, even those 2 cm or less with bland
histologic features [2]. Thus, it is not appropriate to define
any GIST as "benign" per se [5,36,37]. The most reliable
prognostic factors for GIST are size of the primary tumor
and the mitotic index. Additionally, recurrence and sur-
vival rates can be affected by the location of the primary
GIST lesion (e.g. with small bowel and rectal primary
GIST demonstrate worse prognosis than gastric GISTs)
[36,37]. PDGFRA mutations (almost always in gastric pri-
maries) appear to be a very favorable prognostic factor for
low risk of recurrence [38]. Among patients with GIST,
histologic type may also impact prognosis. In a report of
48 patients, the five-year recurrence-free survival rate was
significantly higher among patients with spindle cell as
compared to epithelioid or mixed histology [39]. However,
others report a prognostic influence of the degree of cellu-
larity but not histologic subtype [40,41].
Management paradigms for early-stage GIST
The natural history of early-stage GIST has been docu-
mented in single-institution studies. Two hundred
patients with GIST were followed prospectively at the
Memorial Sloan-Kettering Cancer Center [15]. Eighty of
these patients who had primary disease were managed
with complete surgical resection. This group of patients
demonstrated a 5-year disease-specific survival rate of
54%. On multivariate analysis, large tumor size
(>10 cm) was the only negative predictive factor on
disease-specific survival. Definitive surgery remains the
treatment of choice for patients with localized GIST.
Complete surgical resection is recommended for small
gastric GISTs <2 cm at high risk of recurrence based
upon EUS appearance (irregular borders, cystic spaces,
ulceration, echogenic foci, or heterogeneity in appear-
ance). For tumors that lack these features, endoscopic
surveillance is an option. However, initial therapy with
imatinib may be preferred if a tumor is borderline re-
sectable, or if resection would necessitate extensive
organ disruption. There is no specific consensus or
guideline for the use of neoadjuvant imatinib at this
time. However, this could serve as the initial therapeutic
intervention, with follow-up at close intervals to ensure
appropriate response to therapy. In these situations,
early assessment of therapeutic response by 18FDG-PET
scanning could be very valuable to confirm the response
to imatinib. After maximal response (usually occurring
within 4 to 6 months), definitive surgery could be per-
formed [42].
Adjuvant therapy for resected early-stage GIST
A large multicenter landmark phase 3 trial (ACOSOG
study Z9001) appears to support the use of imatinibtherapy in patients with larger, fully resected, primary
localized GIST lesions at significant risk of relapse [43].
Seven hundred and thirteen adults with a completely
resected primary GIST (>= 3 cm, KIT+) were randomly
assigned to one year of adjuvant imatinib (400 mg daily)
or placebo [43]. The trial was stopped at an early, pre-
planned, event-based interim analysis because of the
positive outcome. At a median follow-up of 20 months,
30 patients in the imatinib group recurred or died, ver-
sus 70 in the placebo group (8 versus 20%). The one-
year relapse-free survival (RFS) rate was 98 versus 83%
favoring imatinib, with a hazard ratio for RFS of 0.35
(95% CI 0.22 to 0.53). In a later analysis, the benefit was
greatest in those with high-risk disease (relapse rate 47
versus 19% for placebo and imatinib, respectively); for
moderate risk disease it was 14 versus 5%, respectively
[44]. Despite prolonged RFS, no benefit in overall sur-
vival (OS) was noted with short follow-up. Furthermore,
after the study was unblinded, all patients randomized to
placebo were allowed to crossover to active treatment,
thus obscuring any potential differences in overall sur-
vival between the groups. Thus, it remains unclear
whether imatinib is simply delaying or really preventing
relapses. The trial tested only the 400 mg daily dose.
Patients with advanced GIST and KIT exon 9 mutations
do better with 800 mg daily doses. Whether doses
greater than 400 mg should be used in the adjuvant set-
ting will require prospective study. Although they were
excluded, these results may also be significant for the 4%
of patients with GISTs that lack KIT overexpression, but
have mutations in KIT or PDGFRA, and can respond to
imatinib [45]. Contrary to this, patients who lack detect-
able KIT or PDGFRA mutations or who have specific
mutations that are known to be resistant to imatinib
may not benefit. Whether such patients should be iden-
tified prospectively and specifically excluded from re-
ceiving adjuvant imatinib is unclear.
The FDA approved the use of imatinib as adjuvant
therapy without any qualification or restriction following
resection of primary GIST ≥3 cm in size, but the Euro-
pean Medicines Agency approved adjuvant imatinib only
for the subset of GIST patients with primary disease that
is judged to be “at significant risk of recurrence” follow-
ing resection.
Estimation of recurrence risk
Several criteria have been proposed, originally to classify
the malignant potential of a GIST. Tumor size, mitotic
rate, and site of tumor origin have gained the greatest
acceptance as being predictive of outcome [46]. Risk
stratification models have also been proposed to distin-
guish prognosis in resected GIST [39]. Tumors arising
from the small bowel, colon, rectum, or mesentery are
associated with less favorable outcomes than those
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approached individually, balancing the estimated prob-
ability of a disease recurrence.
Adjuvant imatinib for 1 year certainly has a major im-
pact on disease control rates, but these differences ap-
pear to fade with increased rates of recurrence noted on
discontinuation of the imatinib dosing. It is possible that
a longer duration of adjuvant therapy might further im-
prove clinical outcomes. A small study of adjuvant ther-
apy for 2 years in Seoul, Korea has shown much higher
rates of disease control than in the 1-year study, consist-
ent with biological expectations [47]. The results of a
trial by the Scandinavian Sarcoma Group (SSG) XVIII
trial were presented at the 2011 American Society of
Clinical Oncology (ASCO) meeting and then published
in 2012. This trial compared 36 versus 12 months of
imatinib (400 mg daily) in 400 patients with high-risk
resected GIST [48]. High-risk was defined as having at
least one of: tumor size >10 cm, mitotic count >10/50
high-power fields (hpf ), tumor size >5 cm with mitotic
rate >5/50 hpf, or tumor rupture. About one-half of the
enrolled patients had gastric primary tumors. At a me-
dian follow-up of 54 months, prolonged treatment was
associated with a significant improvement in RFS, the
primary endpoint (five-year RFS 66 versus 48%, HR 0.46,
95% CI 0.32 to 0.65) as well as OS (92 versus 82%, HR
0.45, 85% CI 0.22 to 0.89). However, twice as many
patients discontinued imatinib for reasons other than
disease progression in the prolonged therapy group (26
versus 13%). This dataset attempts to establish 36 months
of adjuvant imatinib as a new standard for patients with
high-risk resected GIST. In both groups, within 6 to
12 months of discontinuing adjuvant imatinib, rates of
disease recurrence were similarly increased. This and
previous findings seem to support the notion that recur-
rences are just delayed, rather than being prevented. The
question now is whether treatment should be continued
for longer than three years. One study assessed cost-
effectiveness of 3 years versus 1 year of adjuvant imati-
nib in the US from a payer’s perspective [49]. They
reported total lifetime cost per patient at $302,100 with
3 years versus $217,800 for 1 year of imatinib therapy.
They also found that patients on 3 years of imatinib had
higher quality-adjusted life years (QALYs). Thus, incre-
mental cost effectiveness ratio of 3 years versus 1 year of
imatinib therapy was $62,600/QALY. At a threshold of
$100,000/QALY, 3 year imatinib therapy was cost-
effective. At the same meeting Deflin and colleagues
reported on the comparison of the clinical benefit of an
adjuvant therapy in GIST with other adjuvant cancer
therapies [50]. They showed that imatinib has one of the
lowest number needed to treat amongst other adjuvant
treatments, at 1 and 3 year of follow-up. Thus, both clin-
ical and economic results now suggest treating surgicallyresected GIST patients with 3 years of imatinib would
result in improved quality-adjusted and OS.
The Intergroup EORTC 62024 trial with randomization
between two years of imatinib and observation alone has
been completed and is awaiting data maturation. OS is the
primary end point. A single-arm phase II five-year adju-
vant imatinib trial, PERSIST5, has also completed accrual;
data probably will not be available for several years.
Additionally, it is also important to assess whether cer-
tain GIST genotypic subsets benefit more—or fail to
benefit at all—from adjuvant therapy with TKIs. The
ACOSOG Z9001 randomized trial has confirmed certain
differences between the behaviors of genetically different
forms of GIST. The KIT exon 11 deletion confers a
much higher risk of relapse compared with other muta-
tional subtypes in the placebo arm, but these exon 11
mutants benefit from adjuvant imatinib to ablate this
added risk [38]. The PDGFRA-driven GISTs are often
more aggressive in the metastatic setting, however, they
are remarkably indolent with a low risk for relapse fol-
lowing resection of limited-stage primary disease, similar
to the wild type GIST. Given the potential toxicities and
costs of imatinib, as well as the tremendous success of
imatinib for recurrent disease, it is very important that
adjuvant studies of imatinib be completed and analyzed
in the context of molecular subtyping.
Neoadjuvant therapy
There are no published randomized trials addressing the
benefit of neoadjuvant imatinib in the management of
GIST. Since 2003, several case reports and small retro-
spective series have been published. These include a mix
of patients with borderline resectable and unresectable
primary disease, as well as metastatic and locally recur-
rent disease that is potentially amenable to gross resec-
tion [51-57].
The multicenter RTOG (Radiation Therapy Oncology
Group) 0132/ACRIN (American College of Radiology Im-
aging Network) 6665 trial assessed neoadjuvant imatinib
either in primary resectable GIST or as a planned pre-
operative cytoreduction agent for metastatic GIST [58].
Patients with primary GIST (≥5 cm, Group A) or operable
metastatic/recurrent GIST (≥2 cm, Group B) were treated
with neoadjuvant imatinib (600 mg/day) for approximately
two months and maintenance imatinib after surgery for
2 years. The clinical outcomes including progression-free
survival (PFS), disease-specific survival (DSS), and overall
survival (OS) at a median follow-up of 5.1 years were pre-
sented at ASCO 2011 meeting [59]. The authors corre-
lated these endpoints with duration of imatinib therapy.
Sixty-three patients were originally entered (53
analyzable). There were 31 patients in Group A and 22 in
Group B. Estimated 5-year PFS and DSS were 57% A, 30%
B; and 77% A, 77% B, respectively. Estimated 5-year OS
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had not been reached for Group A and was 4.4 years for
Group B. In Group A, 7/11 patients progressed> 2 years
from registration; 6/7 progressing patients had stopped
imatinib prior to progression. In Group B, 10/13 patients
progressed >2 years from registration; 6/10 progressing
patients had stopped imatinib prior to progression. This
long-term analysis suggested a high percentage of patients
progressed after discontinuation of 2-year maintenance
imatinib therapy following surgical resection. This trial
confirmed the safety of neoadjuvant imatinib. The avail-
able data from patients treated for advanced disease sug-
gest that maximal radiographic response to imatinib
generally occurs within three to nine months.
Data from retrospective series also support the benefit
of initial imatinib therapy [52-56,60]. The largest experi-
ence consisted of 46 patients who underwent surgery after
imatinib. Eleven patients had a locally advanced primary
tumor, while 35 had recurrent or metastatic disease [52].
All 11 patients who were treated for a locally advanced
primary tumor (median 12 months of imatinib prior to re-
section had one complete and eight partial responses as
assessed by CT) successfully underwent complete surgical
resection. There was one complete pathologic response.
At a median follow-up of 19.7 months post-resection, all
11 were alive and ten of them were recurrence-free. There
were 11 partial responses among the 35 patients treated
for recurrent/metastatic disease. Eleven patients were able
to undergo a compete resection including two with a
complete pathologic response. Patients with an objective
partial response to imatinib (by CT) were significantly
more likely to undergo a complete resection. All eleven of
the completely resected patients were alive at a median
follow-up of 30.7 months, but six recurred at a median of
15 months, despite continuation of imatinib therapy.
A small trial suggested response rates of up to 70% after
very brief periods of neoadjuvant imatinib (three to seven
days), as assessed by FDG-PET and dynamic CT [61].
However, in this small prospective randomized phase II
trial, there was no evidence of histologic cytoreduction
(and therefore, no potential benefit in terms of reduced
tumor bulk) from≤ 7 days of neoadjuvant imatinib, and
no suggestion that intra-operative blood loss was reduced,
even though blood flow to the tumor was reduced as mea-
sured by dynamic CT. Thus, the clinical benefit of very
short periods of neoadjuvant imatinib (termed "nano-
neoadjuvant therapy") [62] is unproven. It did prove that
radiographic responses and tumor cell apoptosis occur
within the first week of imatinib therapy.
Guidelines from the NCCN recommend initial treat-
ment with imatinib for patients with marginally resectable
tumors and for those who have potentially resectable dis-
ease but with the risk of significant morbidity. A daily dose
of 400 mg per day is the usual approach, although if a KITexon 9 mutation is identified, dose escalation to 800 mg
per day is reasonable. This is also recommended in ESMO
guidelines [63].
Management of metastatic, unresectable or recurrent
GIST
Various mechanisms are responsible for the resistance of
GISTs to conventional cytotoxic chemotherapy. In one
study evaluating the differences in outcome between
GIST and leiomyosarcomas, significantly higher levels of
expression of P-glycoprotein (38.4% vs. 13.4%) and
MRP1 (35.4% vs. 13.3%) were demonstrated in the GIST
cells [64].
During the 1990’s, screening studies [65-67] demon-
strated that a signal transduction inhibitor 571 (STI 571,
imatinib mesylate) inhibits the tyrosine kinase activity of
BCR-ABL as well as KIT. A multicenter US–Finland col-
laborative study enrolled 147 patients with metastatic
GIST between July 2000 and April 2001 [68]. Radio-
graphic responses were seen within six months in 54%
patients. These results along with the outcomes of the
European Organization for Research and Treatment of
Cancer (EORTC) trial 75 [69] confirmed the unparal-
leled activity of imatinib in controlling metastatic GIST.
Despite these excellent results complete responses are
rare (less than 10%), and most patients who initially re-
spond ultimately acquire resistance via additional muta-
tions in KIT. The median time to progression is roughly
two to three years [68,70-72], although it is longer in
other series [73].
Correlative science studies have reported that the type
of mutation in KIT and PDGFRA correlates with clinical
response [74-77]. High dose imatinib may preferentially
benefit patients with exon 9 mutations [77,78]. However,
no differences in OS between low-dose and high-dose
imatinib in patients with exon 9 mutations was seen [79].
Rapid disease progression was seen within months
after the imatinib is stopped [80,81]. At ASCO 2011,
BFR 14 trial reported the effect of interruption of imati-
nib therapy in patients with GIST [82]. At the same
meeting, Domont et al. reported the influence of imati-
nib interruption and reintroduction on tumor burden in
patients with GIST on the BFR 14 trial. Among rando-
mized patients with imatinib interruption 49% experi-
enced progressive disease of the known tumor while
51% had new lesions with concomitant progression of
known lesions [83]. Thus, continuous therapy until dis-
ease progression (or lifelong if disease does not progress)
is currently standard of care.
Imatinib can rapidly and dramatically decrease tumor
avidity for 18FDG [84-86]. With PET imaging, the down-
modulation of tumor avidity for FDG is far earlier than
changes noticeable on CT scanning [68,84,86]. Thus
PET scans can aid in the detection of primary and
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no growth in tumor size or a combination of tumor
density and size criteria have shown a close correlation
with the predictive value results of FDG-PET [22,87].
Imatinib therapy can also change the density of tumor
masses in GIST [22,68,88]. This is an important early
clinical marker of antitumor activity [89,90].
Resistance to imatinib
Clonal evolution of resistant GIST may be detected after
a durable objective response and disease control. Several
mechanisms of resistance to imatinib in GIST may exist
[91,92]. Pharmacokinetic variability may also contribute
to drug resistance [93]. Limited clonal progression
appears as the first sign of resistance to imatinib
[55,92,94]. Dose escalation from imatinib 400 mg daily
may be considered for those with clear evidence of dis-
ease progression [45,95]. Sunitinib targets multiple tyro-
sine kinases, including the vascular endothelial growth
factor receptors and PDGFR. An increasing number of
reports indicate efficacy for the multi-targeted TKI suni-
tinib in imatinib-refractory or intolerant patients [95-
98]. Sunitinib has become the current standard of care
for patients who have failed imatinib.
As with imatinib, the clinical activity of sunitinib is
significantly influenced by the specific mutation type.
Resistance to sunitinib shares similar pathogenetic
mechanisms to those identified in imatinib failure, with
acquisition of secondary mutations after an extended ini-
tial response to the drug [99].
Sorafenib and other TKIs (i.e. sorafenib, dasatinib,
motesanib, nilotinib) have been studied in refractory
GIST or after resistance to imatinib and/or sunitinib
[1,100-105]. The efficacy of sorafenib was addressed in a
multicenter phase II trial involving patients with either
imatinib or imatinib and sunitinib-refractory GIST
[106]. In a preliminary report presented at the 2011
ASCO GI Cancers symposium, the disease control rate
(defined as the proportion of patients without progres-
sion as the best radiologic response) was 68%, and me-
dian PFS was 5.2 months.
Nilotinib was studied in a randomized phase 3 clinical
trial (ENEST g3) [107]. In this trial nilotinib was com-
pared to a heterogeneous control arm in patients
advanced/metastatic GIST who had failed imatinib and
sunitinib. The control arm included best supportive care
with physician choice to continue or stop imatinib or
sunitinib. It failed to show significant benefit for niloti-
nib. Some of the most promising new approaches to
overcome resistance to TKIs in GIST include targeting
multiple levels of the signal transduction cascade by
combining agents. This has been done, for example, by
combining a kinase inhibitor such as imatinib with an
inhibitor of the mTOR downstream signaling partnerusing the mTOR inhibitor everolimus [108]. Other strat-
egies that are being explored include the inhibition of
other pathways critical to the molecular processing of
the mutant KIT or PDGFRA oncoproteins, such as the
chaperone function of the heat shock protein-90 system.
By inhibiting heat shock protein-90, preclinical and early
clinical studies have already documented antineoplastic
effects on kinase-inhibitor-resistant GIST both in vitro
and in patients with progressive disease [109,110].
New prognostic features
The survival was higher in GIST patients who had
PDFGRA mutation as compared to KIT mutations. In
patients with KIT mutations, point mutations and dupli-
cation in KIT axon 11 had better survival than GIST
with other KIT mutations [111].
In a single center study of GIST patients who under-
went curative surgery and were not treated with imati-
nib, the 2 year RFS was lower in patients who had both
557 and 558 codon mutations than in those with either
557 or 558 mutated (p= 0.03) [112].
Hypertension (HTN) is a side effect of drugs with
VEGF signaling pathway inhibition. The relationship be-
tween sunitinib- associated HTN and treatment efficacy
was analyzed. The results significantly favored the
patients who developed HTN while on treatment with
Sunitinib. These patients had significantly prolonged OS,
PFS and TTP as compared to patients who did not de-
velop HTN. Development of HTN during sunitinib ther-
apy may therefore be used as a biomarker for anti-tumor
efficacy [113].
At ASCO GI 2012, a mitotic index of 5/50 HPF was
reported to be equivalent to a standardized uptake value
(SUV) of 4.3, and a Ki67 labeling index of 5 was equiva-
lent to SUV of 6.3 on a PET-CT. Thus, an SUV of 5 can
predict the malignant potential between the high and
low/intermediate risk [114].
D-dimer may be another potential marker in GIST
[115]. Radiological progression (rPD) was associated
with higher d-dimer levels. D-dimer levels <1000 had a
negative predictive value for rPD of 85%. Thus, d-dimer
test may reduce the burden of CT scanning in a useful
percentage of patients but will require further validation.
Recent trends
Billimoria et al. reported the evolution of multimodality
management of GIST with adjuvant and neoadjuvant ther-
apy. They found that between 2001 and 2007 use of adju-
vant therapy with imatinib increased from 27% to 47%.
Use of neo-adjuvant therapy increased from 0% to 15% in
patients with tumors >6 cm [116]. Although the incidence
of GIST increased from 1998 to 2001, it remained stable
from 2001 to 2007. This period also saw a significant de-
crease in patients referred for surgery. Survival of patients
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nosed from 2002–2004 for both resected and unresected
tumor, with resection of the tumor being an independent
predictor of survival [117].
Italiano and co-workers reported the pattern of care, prog-
nosis and survival in patients treated with first line Imatinib
or second line Sunitinib in patients with GIST over 9 centers,
including 176 patients. In the preliminary results they found
that patients having secondary mutations and low serum al-
bumin levels had the worst outcome [118].
Updates from the BFR 14 trial
BFR 14 is a prospective multicenter study from 2002 to
2009 which enrolled 434 patients. Blesius et al. reviewed
236 patients who were started on imatinib 400 mg daily
and had been on it for 5 years. Patients who did not
show any progression were retrospectively analyzed.
They found that patients with small tumor volume at in-
clusion, good performance status, having exon 11 muta-
tion in vicinity of codon 557–558 have higher sensitivity
to imatinib and have a prolonged outcome as compared
to other patients [119]. Bertucci and associates investi-
gated factors predicting long term prognosis in patients
with advanced GIST on the BFR 14 trial. The study
found that female sex, performance status of 0, platelet
count <400,000/dl, lymphocyte count >1500/mm3 were
independent predictors of overall survival. Patients with
CD 34 positivity on tumors have a better PFS [120].
Conclusions and future directions
With the molecular signature of CD117/KIT mutation,
GIST has provided a great model for targeted therapy.
Novel targeted agents are being explored [1]. Combin-
ation therapy of TKI inhibitors either concurrently or se-
quentially with agents of different classes may have
synergistic effects. It is therefore predictable that further
clinical research by combining agents with novel
mechanisms of action for this challenging malignancy
will be forthcoming [121-124].
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